G-CSF dosing schedule to prevent eribulin-induced neutropenia: Can modelling and simulation help?

e20673 Background: Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer and should be administered on day 1 and 8 of each 21-day cycle. Neutrope...